Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis

JACC: Heart Failure

Volumn 4, Issue 4, 2016, Pages 237-248

  Echouffo Tcheugui, Justin B ^a,b   Erqou, Sebhat ^c   Butler, Javed ^d   Yancy, Clyde W ^e   Fonarow, Gregg C ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UCLA MEDICAL CENTER   (United States)

Author keywords

asymptomatic; diastolic dysfunction; heart failure; systolic dysfunction; ventricular dysfunction

Indexed keywords

ARTICLE; ASYMPTOMATIC DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; HEART FAILURE; HUMAN; INCIDENCE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; COMPLICATION; DIASTOLE; GLOBAL HEALTH; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE FUNCTION; MORBIDITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SURVIVAL RATE; SYSTOLE; TRENDS;

ASYMPTOMATIC DISEASES; DIASTOLE; DISEASE PROGRESSION; GLOBAL HEALTH; HEART FAILURE; HUMANS; MORBIDITY; RISK ASSESSMENT; SURVIVAL RATE; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION;

EID: 84949655429     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.09.015     Document Type: Article

References (37)

1. 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2014), e29–e322.
2. 2 Hunt, S.A., Abraham, W.T., Chin, M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 46 (2005), e1–e82.
3. 3 Ammar, K.A., Jacobsen, S.J., Mahoney, D.W., et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 115 (2007), 1563–1570.
4. 4 Wang, T.J., Levy, D., Benjamin, E.J., Vasan, R.S., The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med 138 (2003), 907–916.
5. 5 Lloyd-Jones, D.M., Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation, 2002, 3068–3072.
6. 6 Wang, T.J., Evans, J.C., Benjamin, E.J., Levy, D., LeRoy, E.C., Vasan, R.S., Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108 (2003), 977–982.
7. 7 Lam, C.S.P., Lyass, A., Kraigher-Krainer, E., et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 124 (2011), 24–30.
8. 8 Aurigemma, G.P., Gottdiener, J.S., Shemanski, L., Gardin, J., Kitzman, D., Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 37 (2001), 1042–1048.
9. 9 Pandhi, J., Gottdiener, J.S., Bartz, T.M., Kop, W.J., Mehra, M.R., Comparison of characteristics and outcomes of asymptomatic versus symptomatic left ventricular dysfunction in subjects 65 years old or older (from the Cardiovascular Health Study). Am J Cardiol 107 (2011), 1667–1674.
10. 10 Harris, R.P., Helfand, M., Woolf, S.H., et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 3:Suppl 20 (2001), 21–35.
11. 11 Yeboah, J., Rodriguez, C.J., Stacey, B., et al. Prognosis of individuals with asymptomatic left ventricular systolic dysfunction in the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 126 (2012), 2713–2719.
12. 12 The Cochrane Collaboration. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org. Accessed November 23, 2015.
13. 13 The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992), 685–691.
14. 14 Correa de Sa, D.D., Hodge, D.O., Slusser, J.P., et al. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 96 (2010), 528–532.
15. 15 From, A.M., Scott, C.G., Chen, H.H., The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction: a population-based study. J Am Coll Cardiol 55 (2010), 300–305.
16. 16 Verdecchia, P., Angeli, F., Gattobigio, R., Sardone, M., Porcellati, C., Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension 45 (2005), 412–418.
17. 17 Bibbins-Domingo, K., Pletcher, M.J., Lin, F., et al. Racial differences in incident heart failure among young adults. N Engl J Med 360 (2009), 1179–1190.
18. 18 Ren, X., Ristow, B., Na, B., Ali, S., Schiller, N.B., Whooley, M.A., Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease. Am J Cardiol 99 (2007), 1643–1647.
19. 19 Vogel, M.W., Slusser, J.P., Hodge, D.O., Chen, H.H., The natural history of preclinical diastolic dysfunction: a population-based study. Circ Heart Fail, 2012, 5144–5151.
20. 20 Kane, G.C., Karon, B.L., Mahoney, D.W., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 306 (2011), 856–863.
21. 21 Heart Failure Society of America. Section 7: heart failure in patients with left ventricular systolic dysfunction. J Card Fail 12 (2006), e38–e57.
22. 22 Pfeffer, M.A., Braunwald, E., Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81 (1990), 1161–1172.
23. 23 Mann, D.L., Mechanisms and models in heart failure: a combinatorial approach. Circulation 100 (1999), 999–1008.
24. 24 Cohn, J.N., Ferrari, R., Sharpe, N., Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35 (2000), 569–582.
25. 25 Moss, A.J., Zareba, W., Hall, W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002), 877–883.
26. 26 Kuznetsova, T., Thijs, L., Knez, J., et al. Longitudinal changes in left ventricular diastolic function in a general population. Circ Cardiovasc Imaging, 8, 2015, e002882.
27. 27 Wan, S.-H., Vogel, M.W., Chen, H.H., Pre-clinical diastolic dysfunction. J Am Coll Cardiol 63 (2014), 407–416.
28. 28 Zile, M.R., Baicu, C.F., Ikonomidis, J., et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131 (2015), 1247–1259.
29. 29 Exner, D.V., Dries, D.L., Waclawiw, M.A., Shelton, B., Domanski, M.J., Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 33 (1999), 916–923.
30. 30 Colucci, W.S., Kolias, T.J., Adams, K.F., et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 116 (2007), 49–56.
31. 31 Ledwidge, M., Gallagher, J., Conlon, C., et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310 (2013), 66–74.
32. 32 Bursi, F., Weston, S.A., Redfield, M.M., et al. Systolic and diastolic heart failure in the community. JAMA 296 (2006), 2209–2216.
33. 33 Redfield, M.M., Jacobsen, S.J., Burnett, J.C., Mahoney, D.W., Bailey, K.R., Rodeheffer, R.J., Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003), 194–202.
34. 34 Coglianese, E.E., Wang, T.J., Clinical monitoring of stage B heart failure: echocardiography. Heart Fail Clin 8 (2012), 169–178.
35. 35 Kalogeropoulos, A.P., Georgiopoulou, V.V., Defilippi, C.R., Gottdiener, J.S., Butler, J., Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study. J Am Coll Cardiol Img 5 (2012), 131–140.
36. 36 Gupta, D.K., Solomon, S.D., Imaging in heart failure with preserved ejection fraction. Heart Fail Clin 10 (2014), 419–434.
37. 37 Partington, S.L., Cheng, S., Lima, J.A.C., Cardiac magnetic resonance imaging for stage B heart failure. Heart Fail Clin 8 (2012), 179–190.